Removal of intravenous Intralipid in patients with familial hypercholesterolemia during inhibition of cholesterol absorption and synthesis

Clinica Chimica Acta

Volumn 344, Issue 1-2, 2004, Pages 83-93

  Ketomäki, Anna ^a   Gylling, Helena ^b   Miettinen, Tatu A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

analysis of variance; ANOVA; apo; apolipoprotein; area under the incremental curve; AUIC; Chylomicron; chylomicron; CM; familial hypercholesterolemia; FH; HDL; high density lipoprotein; Intralipid; LDL; Plant stanols; Plant sterols; Squalene; VLDL

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CHYLOMICRON; ESTER DERIVATIVE; INTRALIPID; LIPOPROTEIN; MEVINOLIN; PHYTOSTEROL; SITOSTEROL; SQUALENE; STANOL ESTER; STATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ABSORPTION; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; MALE; MEASUREMENT; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

ABSORPTION; ADULT; CHOLESTEROL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FAT EMULSIONS, INTRAVENOUS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; PHYTOSTEROLS; SITOSTEROLS; SQUALENE; TRIGLYCERIDES;

EID: 2442621422     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2004.02.012     Document Type: Article

References (42)

1. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation. 60:1979;473-485
2. Mahley R.W., Ji Z.S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40:1999;1-16
3. Havel R.J. Chylomicron remnants: hepatic receptors and metabolism. Curr. Opin. Lipidol. 6:1995;312-316
4. Cooper A.D. Hepatic uptake of chylomicron remnants. J. Lipid Res. 38:1997;2173-2192
5. Cabezas M.C., de Bruin T.W., Westerveld H.E., Meijer E., Erkelens D.W. Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolaemia. J. Intern. Med. 244:1998;299-307
6. Eriksson M., Angelin B., Henriksson P., Ericsson S., Vitols S., Berglund L. Metabolism of lipoprotein remnants in humans. Studies during intestinal infusion of fat and cholesterol in subjects with varying expression of the low density lipoprotein receptor. Arterioscler. Thromb. 11:1991;827-837
7. Rubinsztein D.C., Cohen J.C., Berger G.M., van der Westhuyzen D.R., Coetzee G.A., Gevers W. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J. Clin. Invest. 86:1990;1306-1312
8. Mamo J.C., Smith D., Yu K.C., et al. Accumulation of chylomicron remnants in homozygous subjects with familial hypercholesterolaemia. Eur. J. Clin. Invest. 28:1998;379-384
9. Dane-Stewart C.A., Watts G.F., Mamo J.C., Dimmitt S.B., Barrett P.H., Redgrave T.G. Elevated apolipoprotein B-48 and remnant-like particle-cholesterol in heterozygous familial hypercholesterolaemia. Eur. J. Clin. Invest. 31:2001;113-117
10. Parhofer K.G., Barrett P.H., Schwandt P. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemic subjects. J. Clin. Endocrinol. Metab. 85:2000;4224-4230
11. Santos R.D., Sposito A.C., Ventura L.I., Cesar L.A., Ramires J.A., Maranhão R.C. Effect of pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease. Am. J. Cardiol. 85:2000;1163-1166
12. Twickler T.B., Dallinga-Thie G.M., de Valk H.W., et al. High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 20:2000;2422-2427
13. Gylling H., Relas H., Miettinen T.A. Postprandial vitamin A and squalene clearances and cholesterol synthesis off and on lovastatin treatment in type III hyperlipoproteinemia. Atherosclerosis. 115:1995;17-26
14. Heinemann T., Kullak-Ublick G.A., Pietruck B., von Bergmann K. Mechanisms of action of plant sterols on inhibition of cholesterol absorption. Comparison of sitosterol and sitostanol. Eur. J. Clin. Pharmacol. 40(Suppl. 1):1991;S59-S63
15. Vanhanen H.T., Kajander J., Lehtovirta H., Miettinen T.A. Serum levels, absorption efficiency, faecal elimination and synthesis of cholesterol during increasing doses of dietary sitostanol esters in hypercholesterolaemic subjects. Clin. Sci. 87:1994;61-67
16. Miettinen T.A., Vanhanen H. Dietary sitostanol related to absorption, synthesis and serum level of cholesterol in different apolipoprotein E phenotypes. Atherosclerosis. 105:1994;217-226
17. Gylling H., Miettinen T.A. Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetologia. 37:1994;773-780
18. Plat J., Mensink R.P. Effects of plant stanol esters on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase mRNA expression in mononuclear blood cells of healthy men and women. FASEB J. 16:2002;258-260
19. Relas H., Gylling H., Miettinen T.A. Effect of stanol ester on postabsorptive squalene and retinyl palmitate. Metabolism. 49:2000;473-478
20. Carlson L.A., Rössner S. A methodological study of an intravenous fat tolerance test with Intralipid R emulsion. Scand. J. Clin. Lab. Invest. 29:1972;271-280
21. Relas H., Gylling H., Miettinen T.A. Fate of intravenously administered squalene and plant sterols in human subjects. J. Lipid Res. 42:2001;988-994
22. Björkegren J., Packard C.J., Hamsten A., et al. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J. Lipid Res. 37:1996;76-86
23. Hallberg D. Studies on the elimination of exogenous lipids from the blood stream. The kinetics of the elimination of a fat emulsion studied by single injection technique in man. Acta Physiol. Scand. 64:1965;306-313
24. Gylling H., Miettinen T.A. Postabsorptive metabolism of dietary squalene. Atherosclerosis. 106:1994;169-178
25. Rajaratnam R.A., Gylling H., Miettinen T.A. Impaired postprandial clearance of squalene and apolipoprotein B-48 in post-menopausal women with coronary artery disease. Clin. Sci. 97:1999;183-192
26. Krasinski S.D., Cohn J.S., Russell R.M., Schaefer E.J. Postprandial plasma vitamin A metabolism in humans: a reassessment of the use of plasma retinyl esters as markers for intestinally derived chylomicrons and their remnants. Metabolism. 39:1990;357-365
27. Vuorio A.F., Gylling H., Turtola H., Kontula K., Ketonen P., Miettinen T.A. Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation. Arterioscler. Thromb. Vasc. Biol. 20:2000;500-506
28. Aalto-Setälä K., Helve E., Kovanen P.T., Kontula K. Finnish type of low density lipoprotein receptor gene mutation (FH-Helsinki) deletes exons encoding the carboxy-terminal part of the receptor and creates an internalization-defective phenotype. J. Clin. Invest. 84:1989;499-505
29. Koivisto U.M., Turtola H., Aalto-Setälä K., et al. The familial hypercholesterolemia (FH)-North Karelia mutation of the low density lipoprotein receptor gene deletes seven nucleotides of exon 6 and is a common cause of FH in Finland. J. Clin. Invest. 90:1992;219-228
30. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502
31. Miettinen T.A., Koivisto P. Non-cholesterol sterols and bile acid production in hypercholesterolaemic patients with ileal bypass. Paumgartner G., Stiehl A., Gerok W. Bile acids and cholesterol in health disease. 1983;183-187 MTP Press, Lancaster
32. Miettinen T.A. Cholesterol metabolism during ketoconazole treatment in man. J. Lipid Res. 29:1988;43-51
33. Miettinen T.A., Gylling H. Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur. J. Clin. Invest. 33:2003;976-982
34. Thompson G.R., Naoumova R.P., Watts G.F. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J. Lipid Res. 37:1996;439-447
35. Gylling H., Miettinen T.A. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J. Lipid Res. 37:1996;1776-1785
36. Hultin M., Carneheim C., Rosenqvist K., Olivecrona T. Intravenous lipid emulsions: removal mechanisms as compared to chylomicrons. J. Lipid Res. 36:1995;2174-2184
37. Moghadasian M.H., McManus B.M., Godin D.V., Rodrigues B., Frohlich J.J. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. Circulation. 99:1999;1733-1739
38. Tall A. Plasma lipid transfer proteins. Annu. Rev. Biochem. 64:1995;235-257
39. Blair S.N., Capuzzi D.M., Gottlieb S.O., Nguyen T., Morgan J.M., Cater N.B. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am. J. Cardiol. 86:2000;46-52
40. Simons L.A. Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Am. J. Cardiol. 90:2002;737-740
41. Davidson M.H., McGarry T., Bettis R., et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40:2002;2125-2134
42. Assmann G., Cullen P., Erbey J., Ramey D.R., Kannenberg F., Schulte H. Elevation in plasma sitosterol concentration is associated with an increased risk for coronary events in the PROCAM study. Circulation. 108:2003;3300